Gyre Therapeutics (GYRE) Depreciation & Amortization (CF) (2010 - 2026)
Gyre Therapeutics (GYRE) reported Depreciation & Amortization (CF) of $672000.0 for Q1 2026, up 25.61% year-over-year from $535000.0 in Q1 2025, and up 2.44% quarter-over-quarter from $656000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $672000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $672000.0, up 25.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (up 56.86% YoY), and the FY2025 annual result was $2.5 million, up 60.17% from the prior year.
- Depreciation & Amortization (CF) rose to $672000.0 in Q1 2026 per GYRE's latest filing, from $656000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $867000.0 in Q4 2022 and troughed at $40000.0 in Q3 2022.
- A 5-year average of $403705.9 and a median of $415000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 653.91% in 2022, then tumbled 65.63% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $867000.0 in 2022, then plunged by 65.63% to $298000.0 in 2023, then surged by 54.7% to $461000.0 in 2024, then soared by 42.3% to $656000.0 in 2025, then grew by 2.44% to $672000.0 in 2026.
- Business Quant data shows GYRE's Depreciation & Amortization (CF) at $672000.0 in Q1 2026, $656000.0 in Q4 2025, and $649000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 672,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 672,000.00 |
| Mar 31, 2026 | 672,000.00 |
| Dec 31, 2025 | 656,000.00 |
| Dec 31, 2025 | 656,000.00 |
| Sep 30, 2025 | 649,000.00 |
| Sep 30, 2025 | 649,000.00 |
| Jun 30, 2025 | 641,000.00 |
| Jun 30, 2025 | 641,000.00 |
| Mar 31, 2025 | 535,000.00 |
| Mar 31, 2025 | 535,000.00 |
| Dec 31, 2024 | 461,000.00 |
| Dec 31, 2024 | 461,000.00 |
| Sep 30, 2024 | 445,000.00 |
| Sep 30, 2024 | 445,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 415,000.00 |
| Mar 31, 2024 | 415,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Dec 31, 2023 | 298,000.00 |